Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 689 citing articles:

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, et al.
JAMA Oncology (2019) Vol. 5, Iss. 7, pp. 1008-1008
Open Access | Times Cited: 685
Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld, Matthew D. Hellmann
Cancer Cell (2020) Vol. 37, Iss. 4, pp. 443-455
Open Access | Times Cited: 665
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 5, pp. 1111-1122
Open Access | Times Cited: 471
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen
Nature Medicine (2019) Vol. 25, Iss. 3, pp. 389-402
Open Access | Times Cited: 415
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos, Natalie S. Grover, Anne Beaven, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 32, pp. 3794-3804
Open Access | Times Cited: 311
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood (2019) Vol. 134, Iss. 14, pp. 1144-1153
Open Access | Times Cited: 306
Antibody–Drug Conjugates: The Last Decade
Nicolas Joubert, Alain Beck, Charles Dumontet, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 9, pp. 245-245
Open Access | Times Cited: 297
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren, Eva Domingo‐Domènech, Antonio Rueda, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 23, pp. 1997-2007
Open Access | Times Cited: 223
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 4, pp. 512-524
Closed Access | Times Cited: 206
Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
Tomohiro Aoki, Lauren C. Chong, Katsuyoshi Takata, et al.
Cancer Discovery (2019) Vol. 10, Iss. 3, pp. 406-421
Open Access | Times Cited: 197
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud, Antoîne Italiano
Cancers (2020) Vol. 12, Iss. 6, pp. 1502-1502
Open Access | Times Cited: 183
Cancer immunotherapies: advances and bottlenecks
Rui Rui, Liqun Zhou, Shiming He
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 180
Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Jing Nie, Chunmeng Wang, Yang Liu, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 17, pp. 1479-1489
Open Access | Times Cited: 179
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Naval Daver, Ahmad S. Alotaibi, Veit Bücklein, et al.
Leukemia (2021) Vol. 35, Iss. 7, pp. 1843-1863
Open Access | Times Cited: 179
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Hao Wang, Gurbakhash Kaur, Alexander Sankin, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 155
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Justin Kline, James Godfrey, Stephen M. Ansell
Blood (2019) Vol. 135, Iss. 8, pp. 523-533
Open Access | Times Cited: 153
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende, et al.
Intensive Care Medicine (2019) Vol. 45, Iss. 10, pp. 1360-1371
Open Access | Times Cited: 151
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Paul J. Bröckelmann, Helen Goergen, Ulrich Keller, et al.
JAMA Oncology (2020) Vol. 6, Iss. 6, pp. 872-872
Open Access | Times Cited: 147
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Ajjai Alva, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 22, pp. 2443-2451
Closed Access | Times Cited: 145
Immune Checkpoint Inhibitor Therapy in Oncology
Sean Tan, Daphne Day, Stephen J. Nicholls, et al.
JACC CardioOncology (2022) Vol. 4, Iss. 5, pp. 579-597
Open Access | Times Cited: 97
Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
Matthew Mei, Hun Ju Lee, Joycelynne Palmer, et al.
Blood (2022) Vol. 139, Iss. 25, pp. 3605-3616
Open Access | Times Cited: 88
Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
Shovan Dutta, Anirban Ganguly, Kaushiki Chatterjee, et al.
Biology (2023) Vol. 12, Iss. 2, pp. 218-218
Open Access | Times Cited: 75
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
Stephen M. Ansell
American Journal of Hematology (2022) Vol. 97, Iss. 11, pp. 1478-1488
Closed Access | Times Cited: 71
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood (2023) Vol. 142, Iss. 10, pp. 878-886
Open Access | Times Cited: 56
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1379-1389
Closed Access | Times Cited: 36
Page 1 - Next Page

Scroll to top